Table 1.
Baseline clinicopathological characteristics.
| Characteristic | All Patients N 61 (%) |
|---|---|
| Age (years) | |
| Median Age (range) | 67 (30–82) |
| Gender | |
| Male | 50 (82) |
| Female | 11 (18) |
| Baseline PS 1 before nivolumab | |
| 0 | 11 (18) |
| 1 | 34(55.7) |
| 2 | 16 (26.2) |
| Risk factors | |
| Smoking history | 32 (52.5) |
| Alcohol abuse | 17 (27.9) |
| Tumor Location | |
| Oral cavity | 14 (23) |
| Oropharynx | 14 (23) |
| Hypopharynx | 8 (13.1) |
| Larynx | 19(31.1) |
| Other | 6 (9.8) |
| Histology | |
| Squamous Cell Carcinoma | 61 (100) |
| Grading | |
| 2 | 9 (14.8) |
| 3 | 33 (54) |
| Missing | 19 (31.2) |
| HPV 2 | |
| Positive | 2 (3.3) |
| Negative | 11 (18) |
| Not reported | 48 (78.7) |
| Recurrent Disease Metastatic site | 11 (18) |
| 50 (82) | |
| Previous locoregional treatment | 42 (69) |
| Surgery | 9 (14.7) |
| Chemoradiotherapy | 9 (14.7) |
| Surgery and Chemoradiotherapy | 24 (39.3) |
| First line platinum-based chemotherapy | 53 (87) |
| Previous Carboplatin | 27 (44) |
| Previous Cisplatin | 28 (46) |
| Unknown | 6 (10) |
1 PS: performance status; 2 HPV: human papilloma virus.